Drug Profile
Research programme: matrix metalloproteinase-13 inhibitors - Pfizer
Alternative Names: PD 200347Latest Information Update: 14 Aug 2009
Price :
$50
*
At a glance
- Originator Pfizer
- Class
- Mechanism of Action Matrix metalloproteinase 13 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteoarthritis
Most Recent Events
- 16 Sep 2008 Preclinical development is ongoing
- 24 Jun 2004 Preclinical trials in Osteoarthritis in USA (unspecified route)